Market Summary
USD5.04-0.21
Delayedas of 21 Sep 2023, 03:08 pm-4.00%
IOVA Alerts
IOVA Stock Price
IOVA RSI Chart
IOVA Valuation
IOVA Price/Sales (Trailing)
IOVA Profitability
IOVA Fundamentals
IOVA Revenue
IOVA Earnings
Price Action
52 Week Range
4.4110.41
(Low)(High)
Last 7 days
-3.4%
Last 30 days
-16.5%
Last 90 days
-35.3%
Trailing 12 Months
-50.9%
IOVA Financial Health
IOVA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for IOVA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-18 | MCPEAK MERRILL A | bought | 55,600 | 5.56 | 10,000 | - |
2023-09-15 | Rothbaum Wayne P. | bought | 26,500,000 | 5.3 | 5,000,000 | - |
2023-07-14 | GRAF FINCKENSTEIN FRIEDRICH | sold (taxes) | -10,825 | 7.76 | -1,395 | chief medical officer |
2023-07-14 | Vogt Frederick G | sold (taxes) | -68,683 | 7.76 | -8,851 | interim ceo & general counsel |
2023-07-14 | GRAF FINCKENSTEIN FRIEDRICH | acquired | - | - | 2,813 | chief medical officer |
2023-07-14 | Vogt Frederick G | acquired | - | - | 20,834 | interim ceo & general counsel |
2023-07-14 | BILINSKY IGOR | sold (taxes) | -10,825 | 7.76 | -1,395 | chief operating officer |
2023-07-14 | BILINSKY IGOR | acquired | - | - | 2,813 | chief operating officer |
2023-04-14 | BILINSKY IGOR | sold (taxes) | -7,867 | 5.64 | -1,395 | chief operating officer |
2023-04-14 | GRAF FINCKENSTEIN FRIEDRICH | sold (taxes) | -7,867 | 5.64 | -1,395 | chief medical officer |
Which funds bought or sold IOVA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 34.00 | 260 | -% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -8.5 | 5,090,550 | 98,816,300 | 2.86% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 70.7 | 195,164 | 399,164 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | sold off | -100 | -68,432 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 0.61 | 16,500 | 119,480 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 47.18 | 680,504 | 1,658,430 | -% |
2023-08-16 | GTS SECURITIES LLC | new | - | 440,162 | 440,162 | 0.01% |
2023-08-16 | Nuveen Asset Management, LLC | added | 3.42 | 2,524,140 | 15,694,100 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 52.46 | 1,146,140 | 2,660,910 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 3.33 | 4,000 | 24,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
IOVA Alerts
Schedule 13G FIlings of Iovance Biotherapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 17, 2023 | point72 asset management, l.p. | 4.6% | 7,347,600 | SC 13G | |
| Feb 14, 2023 | avoro capital advisors llc | 4.4% | 7,020,000 | SC 13G/A | |
| Feb 14, 2023 | perceptive advisors llc | 6.3% | 9,971,780 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.16% | 14,463,082 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 0.27% | 421,610 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 7.7% | 12,076,276 | SC 13G | |
| Feb 02, 2023 | state street corp | 9.32% | 14,715,475 | SC 13G | |
| Jan 13, 2023 | quogue capital llc | 12.52% | 2e+07 | SC 13D/A | |
| Dec 30, 2022 | mhr fund management llc | 5.8% | 10,511,920 | SC 13G | |
| Feb 24, 2022 | blackrock inc. | 4.7% | 7,408,505 | SC 13G/A |
Recent SEC filings of Iovance Biotherapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 8-K | Current Report | |
| Aug 18, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 10-Q | Quarterly Report | |
| Aug 08, 2023 | 8-K | Current Report | |
| Jul 17, 2023 | 4 | Insider Trading | |
| Jul 17, 2023 | 4 | Insider Trading | |
| Jul 17, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 8-K | Current Report |
Peers (Alternatives to Iovance Biotherapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 4.13% | 21.09% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.16% | 19.51% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -6.80% | -20.18% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.71% | 27.59% | 14.15 | 3.78 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 5.59% | 6.81% | 63.29 | 6.67 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -3.04% | 140.92% | -7.66 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -4.51% | -22.98% | -23.78 | 37.44 | 122.90% | 54.78% |
BEAM | 2.0B | 80.2M | 6.46% | -52.82% | -6.01 | 24.54 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 4.38% | -25.42% | -5.13 | 12.17 | -70.36% | -531.73% |
IOVA | 1.2B | 952.0K | -16.53% | -50.89% | -2.82 | 1.2K | - | -11.27% |
REPL | 980.2M | 15.3M | -15.63% | 3.04% | -5.4 | 64.02 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | -12.64% | -74.33% | -1.13 | 0.42 | 23.74% | 60.24% |
VXRT | 112.7M | 2.1M | -6.14% | -67.90% | -1.12 | 54.83 | 487.70% | -8.66% |
XBIO | 8.7M | 2.2M | 58.19% | 783.63% | -2.08 | 4.04 | 45.07% | 43.77% |
IBIO | 4.1M | - | -12.28% | -96.10% | -0.05 | 3.21 | - | -129.46% |
Iovance Biotherapeutics News
Returns for IOVA
Cumulative Returns on IOVA
0.5%
10-Year Cumulative Returns
-6.3%
7-Year Cumulative Returns
-17.3%
5-Year Cumulative Returns
-47.4%
3-Year Cumulative Returns
Risks for IOVA
What is the probability of a big loss on IOVA?
100%
Probability that Iovance Biotherapeutics stock will be more than 20% underwater in next one year
90.8%
Probability that Iovance Biotherapeutics stock will be more than 30% underwater in next one year.
88.1%
Probability that Iovance Biotherapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does IOVA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Iovance Biotherapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Iovance Biotherapeutics
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |
|---|---|---|
| Description | (%) Q/Q | 2023Q2 |
| Revenue | - | 1.00 |
| S&GA Expenses | - | 104 |
| R&D Expenses | - | 322 |
| Earnings Before Taxes | - | -428 |
| Net Income | - | -418 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -8.2% | 757 | 825 | 664 | 546 | 611 | 701 | 777 | 829 | 853 | 751 | 768 | 782 | 818 | 288 | 345 | 396 | 436 | 462 | 481 | 271 | 285 |
| Current Assets | -56.9% | 275 | 638 | 479 | 370 | 432 | 490 | 508 | 583 | 667 | 605 | 636 | 724 | 783 | 256 | 316 | 367 | 411 | 445 | 475 | 266 | 280 |
| Cash Equivalents | -57.7% | 230 | 544 | 232 | 118 | 108 | 92.00 | 84.00 | 59.00 | 83.00 | 132 | 67.00 | 68.00 | 161 | 53.00 | 19.00 | 39.00 | 77.00 | 54.00 | 82.00 | 81.00 | 246 |
| Inventory | - | 10.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net PPE | 2.4% | 113 | 110 | 105 | 101 | 101 | 103 | 101 | 88.00 | 80.00 | 73.00 | 59.00 | 39.00 | 19.00 | 14.00 | 9.00 | 6.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 |
| Liabilities | 13.2% | 179 | 158 | 164 | 152 | 138 | 149 | 156 | 130 | 108 | 103 | 112 | 70.00 | 59.00 | 45.00 | 46.00 | 41.00 | 39.00 | 27.00 | 15.00 | - | - |
| Current Liabilities | 1.6% | 89.00 | 87.00 | 91.00 | 79.00 | 64.00 | 77.00 | 89.00 | 65.00 | 61.00 | 55.00 | 55.00 | 64.00 | 55.00 | 40.00 | 39.00 | 35.00 | 34.00 | 22.00 | 14.00 | 17.00 | 14.00 |
| Shareholder's Equity | -13.2% | 579 | 667 | 500 | 394 | 473 | 552 | 622 | 698 | 744 | 647 | 656 | 712 | 758 | 243 | 299 | 355 | 397 | 435 | 466 | 254 | 271 |
| Retained Earnings | -6.4% | -1,782 | -1,675 | -1,568 | -1,463 | -1,363 | -1,264 | -1,172 | -1,073 | -986 | -905 | -830 | -761 | -703 | -640 | -570 | -507 | -457 | -410 | 0.00 | -340 | -306 |
| Additional Paid-In Capital | 0.8% | 2,360 | 2,343 | 2,069 | 1,859 | 1,839 | 1,818 | 1,795 | 1,771 | 1,731 | 1,553 | 1,487 | 1,473 | 1,461 | 883 | 869 | 0.00 | 0.00 | 845 | 839 | 594 | 577 |
| Shares Outstanding | 0.1% | 225 | 224 | 188 | 158 | 157 | 157 | 157 | 156 | 154 | 149 | 148 | 147 | 146 | 127 | 126 | 126 | 124 | 123 | 123 | 97.00 | 93.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -5.1% | -335 | -318 | -292 | -268 | -262 | -239 | -227 | -236 | -219 | -202 | -205 | -196 | -197 | -195 | -158 | -136 | -122 | -112 | -101 | -90.66 | -84.18 |
| Share Based Compensation | -7.4% | 72.00 | 77.00 | 84.00 | 84.00 | 83.00 | 75.00 | 70.00 | 61.00 | 52.00 | 48.00 | 41.00 | 36.00 | 32.00 | 28.00 | 24.00 | 24.00 | 23.00 | 22.00 | 20.00 | 17.00 | 15.00 |
| Cashflow From Investing | -78.1% | 71.00 | 323 | 256 | 325 | 264 | 9.00 | 0.00 | -10.45 | -76.16 | -340 | -317 | -349 | -293 | 189 | 90.00 | -143 | -296 | -385 | -386 | -179 | -15.98 |
| Cashflow From Financing | 0.7% | 450 | 447 | 190 | 4.00 | 24.00 | 190 | 239 | 238 | 218 | 623 | 576 | 576 | 575 | 10.00 | 6.00 | 243 | 255 | 255 | 424 | 188 | 232 |
IOVA Income Statement
2023-06-30Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Condensed Consolidated Statements of Operations | ||||
| Total revenue | $ 238 | $ 238 | ||
| Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Product [Member] | Product [Member] | Product [Member] | Product [Member] |
| Costs and expenses | ||||
| Cost of sales | $ 2,050 | $ 2,050 | ||
| Research and development | 86,347 | $ 73,406 | 169,081 | $ 141,706 |
| Selling, general and administrative | 21,927 | 26,328 | 50,049 | 49,741 |
| Total costs and expenses | 110,324 | 99,734 | 221,180 | 191,447 |
| Loss from operations | (110,086) | (99,734) | (220,942) | (191,447) |
| Other income | ||||
| Interest income, net | 3,081 | 385 | 6,567 | 491 |
| Net Loss before income taxes | (107,005) | (99,349) | (214,375) | (190,956) |
| Income tax benefit | 477 | 477 | ||
| Net Loss | $ (106,528) | $ (99,349) | $ (213,898) | $ (190,956) |
| Net Loss Per Share of Common Stock, Basic | $ (0.47) | $ (0.63) | $ (0.98) | $ (1.21) |
| Net Loss Per Share of Common Stock, Diluted | $ (0.47) | $ (0.63) | $ (0.98) | $ (1.21) |
| Weighted Average Shares of Common Stock Outstanding, Basic | 224,481 | 157,274 | 219,117 | 157,194 |
| Weighted Average Shares of Common Stock Outstanding, Diluted | 224,481 | 157,274 | 219,117 | 157,194 |
IOVA Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets | ||
| Cash and cash equivalents | $ 230,010 | $ 231,731 |
| Trade accounts receivable | 33 | |
| Short-term investments | 20,884 | 240,114 |
| Inventory | 9,720 | |
| Prepaid expenses and other assets | 14,231 | 7,271 |
| Total Current Assets | 274,878 | 479,116 |
| Property and equipment, net | 112,549 | 105,232 |
| Intangible assets, net | 235,511 | |
| Operating lease right-of-use assets | 67,631 | 73,015 |
| Restricted cash | 66,430 | 6,430 |
| Long-term assets | 294 | 189 |
| Total Assets | 757,293 | 663,982 |
| Current Liabilities | ||
| Accounts payable | 31,157 | 26,603 |
| Accrued expenses | 46,620 | 52,295 |
| Operating lease liabilities | 10,866 | 12,587 |
| Total Current Liabilities | 88,643 | 91,485 |
| Non-Current Liabilities | ||
| Operating lease liabilities - non-current | 68,844 | 71,859 |
| Deferred tax liabilities | 20,237 | |
| Long-term note payable | 1,000 | 1,000 |
| Total Non-Current Liabilities | 90,081 | 72,859 |
| Total Liabilities | 178,724 | 164,344 |
| Commitments and contingencies | ||
| Stockholders' Equity | ||
| Common stock, $0.000041666 par value; 500,000,000 shares authorized, 224,688,434 and 187,812,072 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 9 | 8 |
| Accumulated other comprehensive income (loss) | 325 | (902) |
| Additional paid-in capital | 2,360,468 | 2,068,867 |
| Accumulated deficit | (1,782,236) | (1,568,338) |
| Total Stockholders' Equity | 578,569 | 499,638 |
| Total Liabilities and Stockholders' Equity | 757,293 | 663,982 |
| Series A Convertible Preferred Stock | ||
| Stockholders' Equity | ||
| Preferred stock, Value | 0 | 0 |
| Series B Convertible Preferred Stock | ||
| Stockholders' Equity | ||
| Preferred stock, Value | $ 3 | $ 3 |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.